CuraTeQ biologics gains EMA GMP certification for biosimilars facility

  • Industry News
  • Nov 13,24
The certification followed an inspection by EMA representatives , which evaluated key areas of the facility.
CuraTeQ biologics gains EMA GMP certification for biosimilars facility

CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has received a Good Manufacturing Practice (GMP) certification from the European Medicines Agency (EMA) for its biosimilars manufacturing facility. The certification followed an inspection by EMA representatives from April 8-12, which evaluated key areas of the facility, including the mammalian and microbial drug substance manufacturing sections, prefilled syringe and vial filling operations, as well as packaging, quality control testing, and release labs.

This successful certification paves the way for the approval of three biosimilars currently under EMA review, anticipated within the next two to five months, according to Satakarni Makkapati, Director and CEO-Biologics, Vaccines, and Peptides, Aurobindo Pharma. K Nithyananda Reddy, Vice-Chairman and Managing Director, noted the company's commitment to developing a robust biosimilars portfolio, with 14 biosimilars in the pipeline targeting therapeutic areas in oncology and immunology, as part of its mission to make essential treatments more accessible to patients.

(The Hindu)

Related Stories

Process Equipment
CuraTeQ biologics gains EMA GMP certification for biosimilars facility

CuraTeQ biologics gains EMA GMP certification for biosimilars facility

The certification followed an inspection by EMA representatives , which evaluated key areas of the facility.

Read more
Process Equipment
Aurobindo to acquire remaining 49% stake in GLS Pharma for Rs 225 million

Aurobindo to acquire remaining 49% stake in GLS Pharma for Rs 225 million

Aurobindo initially acquired a 51% stake in GLS Pharma from promoters Suresh Pathak and his family on June 17, 2022.

Read more
Process Equipment
Pharma firms ask for December 2026 as extension for implementation of rules

Pharma firms ask for December 2026 as extension for implementation of rules

Schedule M of the Drugs and Cosmetics Rules, 1945, outlines good manufacturing practices (GMP) for pharmaceutical products, including a prompt recall system for defective products.

Read more

Related Products

Programmable Controllers - Pcd-33a Series

CHEMICAL PROCESS, FOOD/PHARMA EQUIPMENT & ANALYTICAL INSTRUMENTS

Pro-Med Instruments (P) Ltd offers a wide range of programmable controllers - PCD-33A Series.


Read more

Request a Quote

Gasket Graphite Powder

CHEMICAL PROCESS, FOOD/PHARMA EQUIPMENT & ANALYTICAL INSTRUMENTS

Arihant Packing & Gasket Company offers a wide range of gasket graphite powder. 


Read more

Request a Quote

Asahi Kasei expands 3D printing filament sales in North America

CHEMICAL PROCESS, FOOD/PHARMA EQUIPMENT & ANALYTICAL INSTRUMENTS

Asahi Kasei, a leading resin and compounding technology provider, has initiated the sales of 3D printing (3DP) filaments in North America through Asahi Kasei Plastics North America (APNA). The soft la Read more

Request a Quote

Hi There!

Now get regular updates from IPF Magazine on WhatsApp!

Click on link below, message us with a simple hi, and SAVE our number

You will have subscribed to our Industrial News on Whatsapp! Enjoy

+91 84228 74016